Thursday, February 23, 2017

BRIEF-Oncosec announces positive phase II data for Immunopulse IL-12 in combination with pembrolizumab

* Oncosec announces positive phase ii data demonstrating

company's Immunopulse IL-12 in combination with pembrolizumab

increased response rates in anti-PD-1 non-responder melanoma

patients

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)